Pyrroloquinoline quinone ameliorates L-thyroxine-induced hyperthyroidism and associated problems in rats

Pyrroloquinoline quinone ameliorates L-thyroxine-induced hyperthyroidism and associated problems in rats
复制标题

DOI:
10.1002/cbf.3048
复制
发表时间:
2014-08-01
影响因子:
3.6
通讯作者:
Panda, Sunanda
Panda, Sunanda
中科院分区:
生物学3区
文献类型:
--
作者:
Kumar, Narendra;Kar, Anand;Panda, Sunanda

文献摘要

被引文献

相似文献

吡咯喹啉醌(PQQ)被认为是一种强抗氧化剂。在这项研究中,我们评估了迄今未知的作用,L-甲状腺素(L-T-4)诱导的甲状腺功能亢进症考虑实验室大鼠作为模型。观察血清甲状腺素(T-4)和三碘甲状腺原氨酸(T-3)浓度、肝、肾、心、肌肉和脑的脂质过氧化(LPO)、内源性抗氧化剂如超氧化物歧化酶、过氧化氢酶和谷胱甘肽以及血清总胆固醇、高密度脂蛋白、甘油三酯、血清谷丙转氨酶(SGPT)、血清谷草转氨酶(SGOT)和尿素的变化。给予L-T-4(500 μ g/kg体重)不仅提高了血清T-3和T-4水平,而且提高了组织LPO、血清SGOT、SGPT和尿素水平,同时降低了抗氧化剂和血脂水平。然而,同时给予PQQ(5 mg kg(-1),连续6天),所有这些不良反应均得到改善,表明PQQ在改善甲状腺功能亢进症和相关问题方面的潜力。可能,疗效是通过抑制氧化应激介导的。我们认为,PQQ可考虑用于治疗剂量标准化后的甲状腺功能亢进症。版权所有(C)2014约翰威利父子有限公司
Pyrroloquinoline quinone (PQQ) is believed to be a strong antioxidant. In this study, we have evaluated its hitherto unknown role in L-thyroxin (L-T-4)-induced hyperthyroidism considering laboratory rat as a model. Alterations in the serum concentration of thyroxin (T-4) and triiodothyronine (T-3); lipid peroxidation (LPO) of liver, kidney, heart, muscles and brain; in the endogenous antioxidants such as superoxide dismutase, catalase and glutathione and in serum total cholesterol, high-density lipoprotien, triglycerides, serum glutamate pyruvate transaminase (SGPT), serum glutamate oxaloacetate transaminase (SGOT) and urea were evaluated. Administration of L-T-4 (500-mu g kg (1) body weight) enhanced not only the serum T-3 and T-4 levels but also the tissue LPO, serum SGOT, SGPT and urea with a parallel decrease in the levels of antioxidants and serum lipids. However, on simultaneous administration of PQQ (5mg kg(-1) for 6 days), all these adverse effects were ameliorated, indicating the potential of PQQ in the amelioration of hyperthyroidism and associated problems. Possibly, the curative effects were mediated through inhibition of oxidative stress. We suggest that PQQ may be considered for therapeutic use for hyperthyroidism after dose standardization. Copyright (C) 2014 John Wiley & Sons, Ltd.